Testing a new cell therapy for B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of B-cell lymphoma (like diffuse large B-cell, follicular, or mantle cell lymphoma) that has come back or not responded to treatment.
- Your tumor has the CD19 or BCMA protein (this will be checked with a biopsy or previous test results).
- You have at least one tumor node bigger than 1.5 cm (about the size of a small grape) or a tumor outside the nodes bigger than 1 cm.
- You are in fairly good health (able to do most daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This study tests a new experimental drug called SCTB35 for people with B-cell lymphoma that has come back or stopped responding to treatment. The drug is designed to target a protein on cancer cells (CD20) and may help your immune system fight the lymphoma.
This trial tests a new treatment called JCXH-213 for people with B-cell non-Hodgkin lymphoma that came back or didn't get better after previous treatment. It aims to see if the treatment is safe and works against the cancer.
This trial tests a new cell therapy (called RJMty19) for people with B-cell lymphoma that has returned or not responded to standard treatments. The therapy aims to find and attack cancer cells.
This study is testing a new cellular therapy using immune cells (called CD20/CD19 cells) for patients with a certain type of lymphoma that has not been cured by standard treatments. The cells are designed to find and destroy your lymphoma cells, potentially helping you achieve remission.
This trial tests two new investigational drugs (SCTB35 and SCTB41) alone or with chemotherapy for people with B-cell lymphoma that hasn't responded to previous treatments. The goal is to see if these drugs can help shrink or control the lymphoma.
Hear when a new Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.